March 23 (Reuters) - Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia was now available at U.S. pharmacies for a list price of $1,320 a month.
The U.S. Food and Drug Administration in December approved the drug, Caplyta, as a once-daily dose of 42 mg, which had shown to regulate three neurotransmitter systems linked to severe mental illnesses.
Existing anti-psychotic drugs in the U.S. market include Rexulti from Danish drugmaker H. Lundbeck A/S and Japan's Otsuka Pharmaceutical Co Ltd, Vraylar from Allergan Plc, and Johnson & Johnson's Invega.
The list price for drugs is not necessarily what patients actually pay, as "out-of-pocket" costs vary based on the duration of the treatment and individual healthcare plans. (Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)